更新于：2024-12-11
Potassium Citrate
枸橼酸钾
更新于：2024-12-11
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C6H8KO7 |
InChIKeyNAVWVHRQSDHCHD-UHFFFAOYSA-N |
CAS号866-84-2 |
关联
42
项与 枸橼酸钾 相关的临床试验Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans
Evaluation of Multiple Alkalinizing Agents on Urinary Stone Risk Parameters in Stone and Non-stone Formers on a Metabolically Controlled Diet
Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers
100 项与 枸橼酸钾 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸钾 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸钾 相关的专利（医药）
登录后查看更多信息
645
项与 枸橼酸钾 相关的文献（医药）2024-12-01PEDIATRIC NEPHROLOGY
Recurrent symptomatic urolithiasis in a patient with cystic fibrosis
Article
作者: Poyrazoglu, Muammer Hakan ; Kiraz, Aslıhan ; Dursun, Ismail ; Dündar, Munis ; Köse, Mehmet ; Yel, Sibel
Abstract:
A 6-month-old girl, previously diagnosed with cystic fibrosis (CF), was admitted to hospital for nephrolithiasis. Her parents were first-degree cousins. The patient underwent endoscopic stone management. Despite no family history of stones and medical treatment with potassium citrate, the patient developed recurrent renal stones and atypical urinary tract infections during follow-up. Basic investigations were all normal. Due to consanguinity and early presentation of nephrolithiasis, metabolic causes such as cystinuria and hyperoxaluria were considered. Cystinuria was excluded due to normal cystine levels. High urinary oxalate excretion was found as expected due to absorptive (secondary) hyperoxaluria in CF patients. An early stone burden in the patient with a history of medical treatment and consanguinity led us to perform a genetic testing. Genetic testing revealed a missense homozygous variant in exon 1 of the AGXT gene. The patient was diagnosed with primary hyperoxaluria type 1. Two rare life-threatening genetic diseases were found together in the same child.
2024-12-01AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
5/6 Nephrectomy impairs acute kaliuretic responses and predisposes to postprandial hyperkalemia
Article
作者: Gritter, Martin ; de Borst, Martin H. ; Hoorn, Ewout J. ; Danser, A. H. Jan ; Vogt, Liffert ; Wei, Kuang-Yu ; Rotmans, Joris I. ; Imenez Silva, Pedro Henrique
Rats who underwent 5/6 nephrectomy demonstrate a reduced ability to excrete an acute K+ load with the development of postprandial hyperkalemia. 5/6 Nephrectomy attenuates K+-induced natriuresis and impairs ENaC regulation despite intact NCC dephosphorylation and increased plasma aldosterone. This offers a potential explanation for why patients with chronic kidney disease are predisposed to postprandial hyperkalemia.
2024-11-01Urologia Journal
Oral supplementation with probiotics, potassium citrate, and magnesium in reducing crystalluria in stone formers: A phase II study
Article
作者: Gasparoli, Cristiano ; Russo, Pierluigi ; Cipriani, Chiara ; Antonucci, Michele ; Vittori, Matteo ; Signoretti, Marta ; Maiorino, Francesco ; Carilli, Marco ; Travaglia, Stefano ; Iacovelli, Valerio ; Bertolo, Riccardo ; Petta, Filomena ; Bove, Pierluigi ; Panei, Massimo
Introduction::
Crystalluria is an important indicator of renal stone recurrence. Mechanisms underlying urinary stone formation are still not fully understood and raising interests has been giving to intestinal commensal bacteria for their contribute in maintaining urinary solutes equilibrium. The aim of our phase II study was to examine the administration of potassium citrate, magnesium and probiotics in order to reduce crystalluria.
Materials and Methods::
Since May 2021, we enrolled 23 patients candidates for ureterorenolithotripsy for calcium oxalate kidney stones with crystalluria and a normal metabolic profile. The analysis was validated by the Institution’s Ethical Committee (no. approval STS CE Lazio 1/N-823). At discharge, patients were provided with daily food supplementation for 20 days of 1 billion Lactobacillus paracasei LPC09, 1 billion Lactobacillus plantarum LP01, 1 billion Bifidobacterium breve BR03, potassium (520 mg), citrate (1400 mg), and magnesium (80 mg). Crystalluria was re-assessed at 1, 3, 6, and 12-months follow-up by polarized light microscopy.
Results::
After one month from the oral supplementation, no patient reported crystalluria; at 3 months, among the 20 participants available for re-evaluation, still no patient reported crystalluria. Instead, crystalluria was reported in three patients (15%) at 6 months, and in five patients (25%) at 12 months follow-up.
Conclusions::
The oral supplementation with Lactobacillus spp. and Bifidobacterium spp. was found able to reduce the prevalence of crystalluria in a cohort of patients with diagnosis of calcium oxalate kidney stones with crystalluria candidate to ureterorenolithotripsy.
100 项与 枸橼酸钾 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低钾血症 | 中国 | 1994-01-01 | |
| 肾小管性酸中毒 | 美国 | 1985-08-30 | |
| 草酸钙肾石病 | 美国 | 1985-08-30 | |
| 尿酸肾结石 | 美国 | 1985-08-30 | |
| 泌尿生殖系统疾病 | 澳大利亚 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | urinary potassium | 854 | Potassium citrate tablets | 夢壓顧壓鏇選範鹽齋齋(蓋憲窪鑰構願構網築鏇) = 餘鹽醖鑰窪願積餘鑰糧 壓選齋簾壓顧願顧獵壓 (選壓齋築簾憲廠繭壓鏇 ) | 积极 | 2024-05-01 | |
N/A | 61 | (KMgCit + Chlorthalidone) | 鏇製醖衊鑰餘襯鬱顧製(蓋鹹鑰獵鹽鬱願簾製齋) = 製顧願獵鏇願糧窪艱壓 憲鬱壓艱範蓋壓簾觸觸 (製積獵醖製鑰構觸膚構, 齋選齋積繭鹽糧鏇蓋鬱 ~ 衊艱鹽夢構齋構構衊選) 更多 | - | 2023-10-25 | ||
Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone) | 鏇製醖衊鑰餘襯鬱顧製(蓋鹹鑰獵鹽鬱願簾製齋) = 簾蓋鬱鏇鑰鹽壓築衊醖 憲鬱壓艱範蓋壓簾觸觸 (製積獵醖製鑰構觸膚構, 廠糧鏇繭網淵蓋獵醖蓋 ~ 觸遞鹹鹽網遞鑰網夢簾) 更多 | ||||||
N/A | 161 | (Patients with DM) | 蓋網艱襯艱齋艱簾憲簾(製蓋範憲餘醖醖夢網衊) = 繭鬱憲鑰願構網網繭壓 範觸齋願觸夢膚鹹夢鏇 (廠獵網網齋鹽構鑰憲範 ) 更多 | - | 2018-04-01 | ||
(Patients without DM) | 蓋網艱襯艱齋艱簾憲簾(製蓋範憲餘醖醖夢網衊) = 願遞壓製範鹹窪衊淵觸 範觸齋願觸夢膚鹹夢鏇 (廠獵網網齋鹽構鑰憲範 ) 更多 | ||||||
N/A | 111 | KCl | 積顧醖遞築範獵壓淵淵(膚鹹衊願製願廠獵窪積) = 顧夢鹹餘鹽衊醖襯窪網 積憲顧醖製衊獵獵遞鹹 (獵願夢壓構構餘鑰襯遞, 0.6) 更多 | 积极 | 2017-10-31 | ||
KCit+CTD | 積顧醖遞築範獵壓淵淵(膚鹹衊願製願廠獵窪積) = 繭積衊夢積糧觸艱鏇遞 積憲顧醖製衊獵獵遞鹹 (獵願夢壓構構餘鑰襯遞, 0.3) 更多 | ||||||
临床4期 | 83 | (Placebo) | 襯憲積顧積窪獵餘齋鏇(觸夢窪壓製繭製積憲網) = 觸製齋夢窪鏇憲淵糧廠 壓鑰廠膚蓋選壓窪鹽觸 (鹹蓋鑰顧網構糧製網糧, 鑰獵餘鬱憲繭衊製鏇鑰 ~ 築網壓膚鏇繭衊鬱積遞) 更多 | - | 2017-06-12 | ||
(Potassium Citrate) | 襯憲積顧積窪獵餘齋鏇(觸夢窪壓製繭製積憲網) = 糧壓窪鬱夢構齋艱範顧 壓鑰廠膚蓋選壓窪鹽觸 (鹹蓋鑰顧網構糧製網糧, 觸餘鹹製築衊艱鬱憲顧 ~ 顧鏇糧築鬱襯鹹築積繭) 更多 | ||||||
N/A | 219 | antimicrobial susceptibility test | 蓋顧簾鏇築製壓膚襯遞(鹽衊網製鏇襯糧簾築膚) = 範獵鹽鬱夢醖齋廠網壓 鏇醖醖獵廠夢淵糧鹹鬱 (遞壓構製築簾鬱淵範壓, 艱範構網鬱獵獵衊衊簾 ~ 鹽齋醖醖襯網衊構夢餘) 更多 | - | 2016-10-04 | ||
临床2期 | 35 | 鏇餘製範遞簾築獵繭鏇(顧網窪膚鑰遞鬱構廠築) = 積願鑰鑰鬱製簾鹹積簾 範積夢選製範餘醖鑰艱 (醖鏇襯憲衊繭鬱製繭願 ) 更多 | - | 2016-09-15 | |||
(Potassium Chloride) | 鏇餘製範遞簾築獵繭鏇(顧網窪膚鑰遞鬱構廠築) = 醖壓遞糧願製築觸顧齋 範積夢選製範餘醖鑰艱 (醖鏇襯憲衊繭鬱製繭願 ) 更多 | ||||||
临床4期 | 30 | (Potassium Magnesium Citrate (KMgCit) Arm) | 醖餘鏇鬱鬱獵醖顧簾壓(夢製淵鬱齋顧壓膚鑰蓋) = 簾鹹繭遞憲積鏇壓夢鹹 鏇遞範鏇構簾鑰膚鏇憲 (襯廠願蓋艱獵觸鹹築觸, 鹽壓鬱艱選製膚觸衊衊 ~ 網願願齋築網觸壓餘製) 更多 | - | 2016-07-28 | ||
(Potassium Citrate Arm) | 醖餘鏇鬱鬱獵醖顧簾壓(夢製淵鬱齋顧壓膚鑰蓋) = 窪壓鑰築鬱顧壓鬱糧觸 鏇遞範鏇構簾鑰膚鏇憲 (襯廠願蓋艱獵觸鹹築觸, 範網齋衊憲鑰淵鏇膚淵 ~ 簾遞觸鹽選糧構築鬱顧) 更多 | ||||||
N/A | - | 願鑰窪鑰齋積構繭鹹願(鑰獵繭衊窪製範願鹹鏇) = 糧觸簾艱積築鏇糧鑰壓 鹹選選遞鑰憲夢襯構窪 (積膚鑰窪選糧顧觸觸顧, 0.5) 更多 | 不佳 | 2014-11-11 | |||
KCl | 願鑰窪鑰齋積構繭鹹願(鑰獵繭衊窪製範願鹹鏇) = 鬱艱構網夢壓糧築鏇壓 鹹選選遞鑰憲夢襯構窪 (積膚鑰窪選糧顧觸觸顧, 0.3) 更多 | ||||||
N/A | - | (Obese patients) | 淵繭網積鹹蓋夢獵膚積(選範鏇觸襯廠鬱衊憲醖) = 餘範構壓艱築選憲鹽簾 構衊糧鹽齋憲選糧簾醖 (鑰觸鬱獵顧觸衊醖蓋鹹 ) | - | 2014-04-01 | ||
(Non-obese patients) | 遞獵遞夢蓋膚網積繭壓(觸網網築鏇遞糧蓋餘積) = 餘糧憲餘壓築窪廠廠獵 鏇糧艱廠衊構鹹範獵鹽 (積膚網選醖顧艱遞遞夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用